SCHEMBL6824155

SCHEMBL6824155

COCCOc1ccc(-c2[nH]c3ccc(Cl)cc3c2C2=NCCN2)cc1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.40
NISCH Q9Y2I1 2/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
EIF2AK2 P19525 1/20 0.39
LMNA P02545 1/20 0.39
RECQL P46063 1/20 0.39
MAP2 P11137 1/20 0.39
PARP1 P09874 1/20 0.38
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7736343 0.99 LMNA (0.41) PTGS2NISCHMGAMGAASI
SCHEMBL7736799 0.89 NISCH (0.45) PTGS2NISCHMGAMGAASI
Hydrochloric Acid SCHEMBL7738724 0.88 LMNA (0.43) PTGS2NISCHMGAMGAASI
SCHEMBL6824382 0.87 NISCH (0.54) PTGS2NISCHMGAMGAASI
Hydrochloric Acid SCHEMBL7736206 0.86 NISCH (0.53) PTGS2NISCHMGAMGAASI
SCHEMBL6823645 0.84 LMNA (0.55) PTGS2NISCHLMNARECQLMAP2
Hydrochloric Acid SCHEMBL7727169 0.83 LMNA (0.57) PTGS2NISCHLMNARECQLMAP2
SCHEMBL6824734 0.82 MAP2 (0.40) PTGS2NISCHEIF2AK2MAP2
Hydrochloric Acid SCHEMBL7736339 0.82 LMNA (0.41) PTGS2NISCHMGAMGAASI
SCHEMBL6825016 0.82 NISCH (0.51) PTGS2NISCHLMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R PTGS2 3400/4885NISCH 277/4885MGAM 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.